ISA Pharmaceuticals B.V ▲ Sign in to save

• ▲ Cornelis J.M. Melief

  ISA Pharmaceuticals (Netherlands) Immunology and Microbiology
  33.1k

  citations

  87

  h-index

  28

  Aachen papers
• ▲ Kitty M.C. Kwappenberg

  ISA Pharmaceuticals (Netherlands) Immunology and Microbiology
  3k

  citations

  22

  h-index

  2

  Aachen papers
• ▲ Willem-Jan Krebber

  ISA Pharmaceuticals (Netherlands) Immunology and Microbiology
  2.98k

  citations

  10

  h-index

  9

  Aachen papers
• ▲ Leon W. Hooftman

  ISA Pharmaceuticals (Netherlands) Biochemistry, Genetics and Molecular Biology
  2.7k

  citations

  18

  h-index

  7

  Aachen papers
• ▲ Begoña Aguilera

  ISA Pharmaceuticals (Netherlands) Chemistry
  849

  citations

  15

  h-index

  2

  Aachen papers
• ▲ Anna‐Sophia Wiekmeijer

  ISA Pharmaceuticals (Netherlands) Immunology and Microbiology
  679

  citations

  10

  h-index

  8

  Aachen papers
• ▲ Sonja Visscher

  Medicine
  503

  citations

  6

  h-index

  4

  Aachen papers
• ▲ Marielle Klein Hesselink

  Teva Pharmaceuticals (Netherlands) Medicine
  42

  citations

  4

  h-index

  3

  Aachen papers
• ▲ Femke Sanders

  ISA Pharmaceuticals (Netherlands) Medicine
  18

  citations

  1

  h-index

  1

  Aachen papers

9 results

• Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions

  2022 Journal for ImmunoTherapy of Cancer article Immunology and Microbiology Immunotherapy and Immune Responses Open access

  39

  citations
• Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).

  2024 Journal of Clinical Oncology conference-abstract Medicine Head and Neck Cancer Studies Open access

  18

  citations
• Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy.

  2023 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers

  13

  citations
• Induction of broad multifunctional CD8+ and CD4+ T cells by hepatitis B virus antigen-based synthetic long peptides ex vivo

  2023 Frontiers in Immunology article Medicine Hepatitis B Virus Studies Open access cited by 1 patent

  10

  citations
• Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.

  2021 Journal of Clinical Oncology conference-abstract Immunology and Microbiology Immunotherapy and Immune Responses

  3

  citations
• 1181 Therapeutic vaccines consisting of cancer germline antigen-based synthetic long peptides are immunogenic in human hepatocellular carcinoma patients

  2022 Regular and Young Investigator Award Abstracts conference-abstract Immunology and Microbiology Immunotherapy and Immune Responses Open access

  0

  citations

6 results